US5811447A
(en)
|
1993-01-28 |
1998-09-22 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
US6515009B1
(en)
|
1991-09-27 |
2003-02-04 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
US5981568A
(en)
|
1993-01-28 |
1999-11-09 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
US6491938B2
(en)
|
1993-05-13 |
2002-12-10 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
US6281015B1
(en)
|
1994-12-16 |
2001-08-28 |
Children's Medical Center Corp. |
Localized delivery of factors enhancing survival of transplanted cells
|
US6187757B1
(en)
|
1995-06-07 |
2001-02-13 |
Ariad Pharmaceuticals, Inc. |
Regulation of biological events using novel compounds
|
US5780462A
(en)
*
|
1995-12-27 |
1998-07-14 |
American Home Products Corporation |
Water soluble rapamycin esters
|
GB9606452D0
(en)
*
|
1996-03-27 |
1996-06-05 |
Sandoz Ltd |
Organic compounds
|
US5922730A
(en)
*
|
1996-09-09 |
1999-07-13 |
American Home Products Corporation |
Alkylated rapamycin derivatives
|
US8790391B2
(en)
|
1997-04-18 |
2014-07-29 |
Cordis Corporation |
Methods and devices for delivering therapeutic agents to target vessels
|
US6273913B1
(en)
*
|
1997-04-18 |
2001-08-14 |
Cordis Corporation |
Modified stent useful for delivery of drugs along stent strut
|
US6984635B1
(en)
*
|
1998-02-13 |
2006-01-10 |
Board Of Trustees Of The Leland Stanford Jr. University |
Dimerizing agents, their production and use
|
US6015809A
(en)
*
|
1998-08-17 |
2000-01-18 |
American Home Products Corporation |
Photocyclized rapamycin
|
US6331547B1
(en)
|
1999-08-18 |
2001-12-18 |
American Home Products Corporation |
Water soluble SDZ RAD esters
|
US6277983B1
(en)
|
2000-09-27 |
2001-08-21 |
American Home Products Corporation |
Regioselective synthesis of rapamycin derivatives
|
TWI256395B
(en)
*
|
1999-09-29 |
2006-06-11 |
Wyeth Corp |
Regioselective synthesis of rapamycin derivatives
|
US8236048B2
(en)
|
2000-05-12 |
2012-08-07 |
Cordis Corporation |
Drug/drug delivery systems for the prevention and treatment of vascular disease
|
US6670355B2
(en)
|
2000-06-16 |
2003-12-30 |
Wyeth |
Method of treating cardiovascular disease
|
EP1318837B1
(fr)
|
2000-08-11 |
2004-10-06 |
Wyeth |
Procede de traitement d'un carcinome a recepteur d'oestrogene
|
DE60136200D1
(de)
|
2000-09-19 |
2008-11-27 |
Wyeth Corp |
Wasserlösliche rapamycin-ester
|
US6399625B1
(en)
|
2000-09-27 |
2002-06-04 |
Wyeth |
1-oxorapamycins
|
US20060222756A1
(en)
*
|
2000-09-29 |
2006-10-05 |
Cordis Corporation |
Medical devices, drug coatings and methods of maintaining the drug coatings thereon
|
MXPA03002871A
(es)
|
2000-09-29 |
2004-12-06 |
Johnson & Johnson |
Dispositivos medicos recubiertos.
|
US20070276474A1
(en)
*
|
2000-09-29 |
2007-11-29 |
Llanos Gerard H |
Medical Devices, Drug Coatings and Methods for Maintaining the Drug Coatings Thereon
|
US6440991B1
(en)
|
2000-10-02 |
2002-08-27 |
Wyeth |
Ethers of 7-desmethlrapamycin
|
US6399626B1
(en)
*
|
2000-10-02 |
2002-06-04 |
Wyeth |
Hydroxyesters of 7-desmethylrapamycin
|
TWI286074B
(en)
|
2000-11-15 |
2007-09-01 |
Wyeth Corp |
Pharmaceutical composition containing CCI-779 as an antineoplastic agent
|
US6821731B2
(en)
|
2000-11-28 |
2004-11-23 |
Wyeth |
Expression analysis of FKBP nucleic acids and polypeptides useful in the diagnosis of prostate cancer
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
ES2728739T3
(es)
|
2001-02-19 |
2019-10-28 |
Novartis Pharma Ag |
Derivado de rapamicina para el tratamiento de un tumor sólido asociado con angiogénesis desregulada
|
TWI233359B
(en)
*
|
2001-04-06 |
2005-06-01 |
Wyeth Corp |
Pharmaceutical composition for treating neoplasm
|
CN1309421C
(zh)
*
|
2001-04-06 |
2007-04-11 |
惠氏公司 |
诸如雷帕霉素和吉西他滨或氟尿嘧啶的抗肿瘤联合
|
TWI296196B
(en)
*
|
2001-04-06 |
2008-05-01 |
Wyeth Corp |
Antineoplastic combinations
|
ZA200603888B
(en)
*
|
2001-06-01 |
2007-05-30 |
Wyeth Corp |
Antineoplastic combinations
|
UA77200C2
(en)
|
2001-08-07 |
2006-11-15 |
Wyeth Corp |
Antineoplastic combination of cci-779 and bkb-569
|
DE60206512T2
(de)
|
2001-08-22 |
2006-06-22 |
Wyeth |
Rapamycin 29-enole
|
US6680330B2
(en)
|
2001-08-22 |
2004-01-20 |
Wyeth |
Rapamycin dialdehydes
|
US6939376B2
(en)
*
|
2001-11-05 |
2005-09-06 |
Sun Biomedical, Ltd. |
Drug-delivery endovascular stent and method for treating restenosis
|
US7682387B2
(en)
*
|
2002-04-24 |
2010-03-23 |
Biosensors International Group, Ltd. |
Drug-delivery endovascular stent and method for treating restenosis
|
EP2407473A3
(fr)
|
2002-02-01 |
2012-03-21 |
ARIAD Pharmaceuticals, Inc |
Procédé de préparation de composés contenant du phosphore
|
US20040024450A1
(en)
*
|
2002-04-24 |
2004-02-05 |
Sun Biomedical, Ltd. |
Drug-delivery endovascular stent and method for treating restenosis
|
CA2483594C
(fr)
|
2002-05-16 |
2011-02-15 |
Novartis Ag |
Utilisation d'agents de liaison du recepteur edg dans le cancer
|
US7217796B2
(en)
*
|
2002-05-24 |
2007-05-15 |
Schering Corporation |
Neutralizing human anti-IGFR antibody
|
CA2486853A1
(fr)
|
2002-05-27 |
2003-12-04 |
Novartis Ag |
Alcanols bi-aromatiques
|
AU2003247483A1
(en)
*
|
2002-05-30 |
2003-12-31 |
The Children's Hospital Of Philadelphia |
Methods for treatment of acute lymphocytic leukemia
|
ES2296063T3
(es)
|
2002-07-16 |
2008-04-16 |
Biotica Technology Limited |
Produccion de poliquetidos y otros productos naturales.
|
CA2493878C
(fr)
|
2002-07-30 |
2013-07-23 |
Wyeth |
Formulations parenterales contenant un hydroxyester de rapamycine
|
RU2005106855A
(ru)
*
|
2002-08-12 |
2005-10-10 |
Дзе Риджентс оф дзе Юниверсити оф Мичиган (US) |
Диагностика и лечение заболеваний, вызываемых дефектами каскада реакций, обусловливающих туберозный склероз
|
MXPA05002828A
(es)
*
|
2002-09-17 |
2005-05-27 |
Wyeth Corp |
Formulaciones orales.
|
EP1539270A1
(fr)
*
|
2002-09-18 |
2005-06-15 |
Medtronic Vascular, Inc. |
Revetement a gradient de liberation de medicament controlee pour dispositifs medicaux
|
US20060046979A1
(en)
|
2002-09-24 |
2006-03-02 |
Foster Carolyn A |
Organic compounds
|
WO2004060283A2
(fr)
|
2002-12-16 |
2004-07-22 |
Nitromed, Inc. |
Composes a base de rapamycine nitrosee et nitrosylee, compositions et procedes d'utilisation
|
WO2004069159A2
(fr)
*
|
2003-01-27 |
2004-08-19 |
Endocyte, Inc. |
Conjugues de delivrance de medicaments de liaison au recepteur de vitamines
|
AR042938A1
(es)
*
|
2003-02-06 |
2005-07-06 |
Wyeth Corp |
Uso del cci-779 en el tratamiento de la fibrosis hepatica
|
UA83484C2
(uk)
*
|
2003-03-05 |
2008-07-25 |
Уайт |
Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
|
US20040258662A1
(en)
*
|
2003-04-22 |
2004-12-23 |
Wyeth |
Antineoplastic agents
|
US20040213757A1
(en)
*
|
2003-04-23 |
2004-10-28 |
Wyeth Holdings Corporation |
Water soluble wortmannin derivatives
|
US7160867B2
(en)
*
|
2003-05-16 |
2007-01-09 |
Isotechnika, Inc. |
Rapamycin carbohydrate derivatives
|
MXPA05012461A
(es)
|
2003-05-19 |
2006-02-22 |
Irm Llc |
Compuestos y composiciones inmunosupresores.
|
MY150088A
(en)
|
2003-05-19 |
2013-11-29 |
Irm Llc |
Immunosuppressant compounds and compositions
|
TW200500065A
(en)
*
|
2003-05-21 |
2005-01-01 |
Wyeth Corp |
Antiarthritic combinations
|
CA2526120A1
(fr)
*
|
2003-06-03 |
2005-02-24 |
Cell Genesys, Inc. |
Compositions et methodes pour une expression amelioree de polypeptides recombinants a partir d'un vecteur unique, faisant appel a un site de clivage peptidique
|
US20050136035A1
(en)
*
|
2003-06-03 |
2005-06-23 |
Derek Ko |
Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
|
WO2005010010A1
(fr)
*
|
2003-07-16 |
2005-02-03 |
Wyeth |
Isomere c cci-779
|
CN1829514A
(zh)
*
|
2003-07-25 |
2006-09-06 |
惠氏公司 |
Cci-779冻干制剂
|
KR20060057605A
(ko)
*
|
2003-08-07 |
2006-05-26 |
와이어쓰 |
Cci-779의 위치선택적 합성 방법
|
JP2007504226A
(ja)
*
|
2003-09-03 |
2007-03-01 |
ワイス |
非晶質状のラパマイシンの3−ヒドロキシ−2−(ヒドロキシメチル)−2−メチルプロピオン酸との42−エステル、およびそれを含むその医薬組成物
|
AR046194A1
(es)
*
|
2003-11-04 |
2005-11-30 |
Mayo Foundation |
Metodo de tratamiento del linfoma de celulas del manto
|
US7220755B2
(en)
|
2003-11-12 |
2007-05-22 |
Biosensors International Group, Ltd. |
42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
|
PE20050928A1
(es)
*
|
2003-11-21 |
2005-11-08 |
Schering Corp |
Combinaciones terapeuticas de anticuerpo anti-igfr1
|
MXPA06007829A
(es)
*
|
2004-01-08 |
2006-09-01 |
Wyeth Corp |
Composicion farmaceutica directamente comprimible para la administracion oral de 42-ester de rapamicina con acido 3-hidroxi-2-(hidroximetil)-2-metilpropionico.
|
AR047988A1
(es)
*
|
2004-03-11 |
2006-03-15 |
Wyeth Corp |
Combinaciones antineoplásicas de cci-779 y rituximab
|
BRPI0509580A
(pt)
*
|
2004-03-30 |
2007-11-27 |
Pfizer Prod Inc |
combinações de inibidores de transdução de sinal
|
US7202256B2
(en)
|
2004-04-14 |
2007-04-10 |
Wyeth |
Proline CCI-779, production of and uses therefor, and two-step enzymatic synthesis of proline CCI-779 and CCI-779
|
ATE410431T1
(de)
*
|
2004-04-14 |
2008-10-15 |
Wyeth Corp |
Verfahren zur herstellung von rapamycin-42-estern und fk-506-32-estern mit dicarbonsäure, vorstufen für rapamycinkonjugate und antikörper
|
SG152234A1
(en)
*
|
2004-04-14 |
2009-05-29 |
Wyeth Corp |
Regiospecific synthesis of rapamycin 42-ester derivatives
|
BRPI0510277A
(pt)
*
|
2004-04-27 |
2007-10-30 |
Wyeth Corp |
método para marcar especificamente uma rapamicina, rapamicina especificamente marcada, composição, e, kit
|
WO2006115509A2
(fr)
|
2004-06-24 |
2006-11-02 |
Novartis Vaccines And Diagnostics Inc. |
Immuno-potentialisateurs a petites molecules et analyses visant a detecter leur presence
|
CA2573656A1
(fr)
*
|
2004-07-13 |
2006-02-16 |
Cell Genesys, Inc. |
Compositions de vecteurs aav et procedes pour l'expression accrue d'immunoglobulines utilisant celles-ci
|
WO2006012527A1
(fr)
|
2004-07-23 |
2006-02-02 |
Endocyte, Inc. |
Groupes de liaison bivalents et conjugués de ceux-ci
|
AU2005292647A1
(en)
*
|
2004-08-10 |
2006-04-13 |
Wyeth |
CCI-779 derivatives and methods of making same
|
GB0417852D0
(en)
|
2004-08-11 |
2004-09-15 |
Biotica Tech Ltd |
Production of polyketides and other natural products
|
US7901451B2
(en)
|
2004-09-24 |
2011-03-08 |
Biosensors International Group, Ltd. |
Drug-delivery endovascular stent and method for treating restenosis
|
AU2005294382A1
(en)
*
|
2004-10-04 |
2006-04-20 |
Qlt Usa, Inc. |
Ocular delivery of polymeric delivery formulations
|
US8313763B2
(en)
*
|
2004-10-04 |
2012-11-20 |
Tolmar Therapeutics, Inc. |
Sustained delivery formulations of rapamycin compounds
|
US20080221660A1
(en)
*
|
2004-10-28 |
2008-09-11 |
Medtronic Vascular, Inc. |
Platelet Gel for Treatment of Aneurysms
|
RU2007112787A
(ru)
*
|
2004-10-28 |
2008-12-10 |
Вайет (Us) |
ПРИМЕНЕНИЕ ИНГИБИТОРА mTOR ПРИ ЛЕЧЕНИИ ЛЕЙОМИОМЫ МАТКИ
|
US8021849B2
(en)
*
|
2004-11-05 |
2011-09-20 |
Siemens Healthcare Diagnostics Inc. |
Methods and kits for the determination of sirolimus in a sample
|
WO2006084058A2
(fr)
|
2005-02-03 |
2006-08-10 |
The General Hospital Corporation |
Methode de traitement du cancer resistant au gefitinib
|
KR20070107030A
(ko)
*
|
2005-02-09 |
2007-11-06 |
와이어쓰 |
Cci-779 다형체 및 그의 용도
|
MX2007009812A
(es)
*
|
2005-02-15 |
2007-10-23 |
Wyeth Corp |
Formulaciones en tableta de 42-ester de rapamicina con acido 3-hidroxi-2-(hidroximetil)-2-metilpropionico oralmente biodisponibles.
|
GB0503936D0
(en)
*
|
2005-02-25 |
2005-04-06 |
San Raffaele Centro Fond |
Method
|
CA2599582A1
(fr)
*
|
2005-03-02 |
2006-09-08 |
Wyeth |
Purification de la rapamycine
|
AU2006218916A1
(en)
*
|
2005-03-02 |
2006-09-08 |
Wyeth |
Recovery of CCI-779 from mother liquors
|
GB0504544D0
(en)
|
2005-03-04 |
2005-04-13 |
Novartis Ag |
Organic compounds
|
EP1896018A2
(fr)
|
2005-03-11 |
2008-03-12 |
Biotica Technology Limited |
Utilisations medicales de 39-demethoxy-rapamicyne et ses analogues
|
US20100061994A1
(en)
*
|
2005-03-11 |
2010-03-11 |
Rose Mary Sheridan |
Medical uses of 39-desmethoxyrapamycin and analogues thereof
|
GB0504994D0
(en)
*
|
2005-03-11 |
2005-04-20 |
Biotica Tech Ltd |
Novel compounds
|
JP5289935B2
(ja)
*
|
2005-03-16 |
2013-09-11 |
エンドサイト,インコーポレイテッド |
プテロイン酸およびその結合体の合成と精製
|
US20060233810A1
(en)
*
|
2005-04-15 |
2006-10-19 |
Yaolin Wang |
Methods and compositions for treating or preventing cancer
|
US7189582B2
(en)
*
|
2005-04-27 |
2007-03-13 |
Dade Behring Inc. |
Compositions and methods for detection of sirolimus
|
US20070004767A1
(en)
*
|
2005-06-30 |
2007-01-04 |
Gutmann David H |
Methods for treating neurofibromatosis 1
|
CA2615452C
(fr)
|
2005-07-15 |
2015-03-31 |
Micell Technologies, Inc. |
Enrobages polymeres renfermant de la poudre de medicament a morphologie commandee
|
WO2007011708A2
(fr)
|
2005-07-15 |
2007-01-25 |
Micell Technologies, Inc. |
Stent a revetement polymere renfermant de la rapamycine amorphe
|
US7632509B2
(en)
*
|
2005-07-19 |
2009-12-15 |
Biosante Pharmaceuticals, Inc. |
Methods to express recombinant proteins from lentiviral vectors
|
RS54088B1
(en)
|
2005-07-25 |
2015-10-30 |
Emergent Products Development Seattle Llc |
B-CELL REDUCTION BY USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES
|
ES2468240T3
(es)
|
2005-08-19 |
2014-06-16 |
Endocyte, Inc. |
Conjugados de ligando de múltiples fármacos
|
WO2007024501A2
(fr)
|
2005-08-25 |
2007-03-01 |
Medtronic Vascular, Inc. |
Polymeres biodegradables liberant de l'oxyde nitrique utiles comme dispositifs medicaux et revetements associes
|
ES2611307T3
(es)
|
2005-08-30 |
2017-05-08 |
University Of Miami |
Inmunomodulación de agonistas, antagonistas e inmunotoxinas del receptor del factor de necrosis tumoral 25 (TNFR25)
|
WO2007056118A1
(fr)
|
2005-11-04 |
2007-05-18 |
Wyeth |
Combinaisons antineoplasiques a base d'inhibiteur de mtop, d'herceptine et/ou de khi-272
|
WO2007056175A2
(fr)
*
|
2005-11-04 |
2007-05-18 |
Wyeth |
42-ester de rapamycine marque par isotope par un 41-methoxy
|
RU2008121240A
(ru)
*
|
2005-12-07 |
2010-01-20 |
Вайет (Us) |
Способ получения очищенного кристаллического cci-779
|
CA2630645A1
(fr)
*
|
2005-12-07 |
2007-06-14 |
Wyeth |
Procede evolutif pour la preparation d'un 42-ester de rapamycine a partir d'un borate de 42-ester de rapamycine
|
WO2007067566A2
(fr)
*
|
2005-12-07 |
2007-06-14 |
Wyeth |
Procédés destinés à préparer de la rapamycine cristalline et à mesurer la cristallinité de composés de rapamycine au moyen d'une analyse calorimétrique à compensation de puissance
|
LT1983984T
(lt)
*
|
2006-02-02 |
2018-06-11 |
Novartis Ag |
Tuberozinės sklerozės gydymas
|
US20070203169A1
(en)
*
|
2006-02-28 |
2007-08-30 |
Zhao Jonathon Z |
Isomers and 42-epimers of rapamycin ester analogs, methods of making and using the same
|
US7605257B2
(en)
*
|
2006-03-07 |
2009-10-20 |
Wyeth |
Processes for preparing water-soluble polyethylene glycol conjugates of macrolide immunosuppressants
|
DE102006011507A1
(de)
*
|
2006-03-14 |
2007-09-20 |
Lts Lohmann Therapie-Systeme Ag |
Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine
|
US20070292922A1
(en)
*
|
2006-03-31 |
2007-12-20 |
Cell Genesys, Inc. |
Regulated expression of recombinant proteins from adeno-associated viral vectors
|
CA2650590C
(fr)
|
2006-04-26 |
2018-04-03 |
Micell Technologies, Inc. |
Revetements contenant plusieurs medicaments
|
US8241619B2
(en)
|
2006-05-15 |
2012-08-14 |
Medtronic Vascular, Inc. |
Hindered amine nitric oxide donating polymers for coating medical devices
|
GB0609962D0
(en)
*
|
2006-05-19 |
2006-06-28 |
Biotica Tech Ltd |
Novel compounds
|
GB0609963D0
(en)
*
|
2006-05-19 |
2006-06-28 |
Biotica Tech Ltd |
Novel compounds
|
WO2008053362A2
(fr)
*
|
2006-06-30 |
2008-05-08 |
Interface Biologics, Inc. |
Polymères biosensibles
|
US20080207671A1
(en)
*
|
2006-07-31 |
2008-08-28 |
The Regents Of The University Of Michigan |
Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway
|
WO2008016633A2
(fr)
*
|
2006-08-02 |
2008-02-07 |
Ariad Gene Therapeutics, Inc. |
Thérapie par combinaison
|
RU2010104916A
(ru)
*
|
2006-08-16 |
2011-08-20 |
Михаил В. Благосклонный (US) |
Способ профилактики и лечения возрастных заболеваний
|
US20080051691A1
(en)
*
|
2006-08-28 |
2008-02-28 |
Wyeth |
Implantable shunt or catheter enabling gradual delivery of therapeutic agents
|
CN104906087A
(zh)
|
2006-09-13 |
2015-09-16 |
万能医药公司 |
大环内酯化合物及它们的使用方法
|
TW200824713A
(en)
*
|
2006-10-18 |
2008-06-16 |
Wyeth Corp |
Processes for the synthesis of individual isomers of mono-PEG CCI-779
|
US20080097591A1
(en)
*
|
2006-10-20 |
2008-04-24 |
Biosensors International Group |
Drug-delivery endovascular stent and method of use
|
US8067055B2
(en)
|
2006-10-20 |
2011-11-29 |
Biosensors International Group, Ltd. |
Drug-delivery endovascular stent and method of use
|
US7691402B2
(en)
*
|
2006-11-06 |
2010-04-06 |
Medtronic Vascular, Inc. |
Block biodegradable copolymers for medical devices
|
EP2099443A4
(fr)
*
|
2006-11-10 |
2010-05-05 |
Syndax Pharmaceuticals Inc |
Association de ligands de era+ et d'inhibiteurs de l'histone désacétylase dans le traitement du cancer
|
US8414525B2
(en)
|
2006-11-20 |
2013-04-09 |
Lutonix, Inc. |
Drug releasing coatings for medical devices
|
US9737640B2
(en)
|
2006-11-20 |
2017-08-22 |
Lutonix, Inc. |
Drug releasing coatings for medical devices
|
US8414526B2
(en)
|
2006-11-20 |
2013-04-09 |
Lutonix, Inc. |
Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
|
US8414910B2
(en)
|
2006-11-20 |
2013-04-09 |
Lutonix, Inc. |
Drug releasing coatings for medical devices
|
US9700704B2
(en)
|
2006-11-20 |
2017-07-11 |
Lutonix, Inc. |
Drug releasing coatings for balloon catheters
|
US20080276935A1
(en)
|
2006-11-20 |
2008-11-13 |
Lixiao Wang |
Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
|
US8998846B2
(en)
|
2006-11-20 |
2015-04-07 |
Lutonix, Inc. |
Drug releasing coatings for balloon catheters
|
US8425459B2
(en)
|
2006-11-20 |
2013-04-23 |
Lutonix, Inc. |
Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
|
US8414909B2
(en)
|
2006-11-20 |
2013-04-09 |
Lutonix, Inc. |
Drug releasing coatings for medical devices
|
US8430055B2
(en)
|
2008-08-29 |
2013-04-30 |
Lutonix, Inc. |
Methods and apparatuses for coating balloon catheters
|
JP5456321B2
(ja)
|
2006-11-27 |
2014-03-26 |
テルモ株式会社 |
O−アルキル化ラパマイシン誘導体の製造方法およびo−アルキル化ラパマイシン誘導体
|
CN101711137B
(zh)
|
2007-01-08 |
2014-10-22 |
米歇尔技术公司 |
具有可生物降解层的支架
|
US11426494B2
(en)
|
2007-01-08 |
2022-08-30 |
MT Acquisition Holdings LLC |
Stents having biodegradable layers
|
US7753962B2
(en)
*
|
2007-01-30 |
2010-07-13 |
Medtronic Vascular, Inc. |
Textured medical devices
|
US20080188461A1
(en)
*
|
2007-02-01 |
2008-08-07 |
Regents Of The University Of Michigan |
Compositions and methods for detecting, preventing and treating seizures and seizure related disorders
|
WO2008101231A2
(fr)
|
2007-02-16 |
2008-08-21 |
Endocyte, Inc. |
Procédés et compositions de traitement et de diagnostic d'une maladie rénale
|
US7815927B2
(en)
*
|
2007-03-08 |
2010-10-19 |
Medtronic Vascular, Inc. |
Terpolymers for controlled release of bioactive agents from implantable medical devices
|
US7811600B2
(en)
*
|
2007-03-08 |
2010-10-12 |
Medtronic Vascular, Inc. |
Nitric oxide donating medical devices and methods of making same
|
CN101678124A
(zh)
|
2007-03-14 |
2010-03-24 |
恩多塞特公司 |
结合配体连接的微管溶素递药缀合物
|
TW200845960A
(en)
*
|
2007-04-05 |
2008-12-01 |
Wyeth Corp |
Wortmannin-rapalog conjugate and uses thereof
|
US20080245375A1
(en)
*
|
2007-04-05 |
2008-10-09 |
Medtronic Vascular, Inc. |
Benign Prostatic Hyperplasia Treatments
|
TW200901989A
(en)
|
2007-04-10 |
2009-01-16 |
Wyeth Corp |
Anti-tumor activity of CCI-779 in papillary renal cell cancer
|
US9433516B2
(en)
|
2007-04-17 |
2016-09-06 |
Micell Technologies, Inc. |
Stents having controlled elution
|
US20080306581A1
(en)
*
|
2007-06-07 |
2008-12-11 |
Medtronic Vascular, Inc. |
Streamlined Stents
|
US9877965B2
(en)
|
2007-06-25 |
2018-01-30 |
Endocyte, Inc. |
Vitamin receptor drug delivery conjugates for treating inflammation
|
EP3569251A1
(fr)
|
2007-06-25 |
2019-11-20 |
Endocyte, Inc. |
Conjugués contenant des lieurs espaceurs hydrophiles
|
US8852620B2
(en)
|
2007-07-20 |
2014-10-07 |
Medtronic Vascular, Inc. |
Medical devices comprising polymeric drug delivery systems with drug solubility gradients
|
US8273828B2
(en)
*
|
2007-07-24 |
2012-09-25 |
Medtronic Vascular, Inc. |
Methods for introducing reactive secondary amines pendant to polymers backbones that are useful for diazeniumdiolation
|
US20090043378A1
(en)
*
|
2007-08-10 |
2009-02-12 |
Medtronic Vascular, Inc. |
Biocompatible Polymer System for Extended Drug Release
|
US20090076060A1
(en)
*
|
2007-09-17 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched temsirolimus
|
KR100930167B1
(ko)
*
|
2007-09-19 |
2009-12-07 |
삼성전기주식회사 |
초광각 광학계
|
JP5599712B2
(ja)
|
2007-10-05 |
2014-10-01 |
インターフェース バイオロジクス,インコーポレーテッド |
オリゴフッ素化架橋ポリマーおよびそれの使用
|
US8022216B2
(en)
|
2007-10-17 |
2011-09-20 |
Wyeth Llc |
Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
|
US20110104228A1
(en)
|
2007-10-19 |
2011-05-05 |
Interface Biologics, Inc |
Self-eliminating coatings
|
US20090131367A1
(en)
*
|
2007-11-19 |
2009-05-21 |
The Regents Of The University Of Colorado |
Combinations of HDAC Inhibitors and Proteasome Inhibitors
|
WO2009089549A1
(fr)
*
|
2008-01-11 |
2009-07-16 |
Massachusetts Eye & Ear Infirmary |
Animaux transgéniques de caspase dimérisable d'arrêt conditionnel
|
US20090222088A1
(en)
*
|
2008-02-29 |
2009-09-03 |
Medtronic Vascular, Inc. |
Secondary Amine Containing Nitric Oxide Releasing Polymer Composition
|
US20100048912A1
(en)
|
2008-03-14 |
2010-02-25 |
Angela Brodie |
Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
|
US20090232868A1
(en)
*
|
2008-03-17 |
2009-09-17 |
Medtronic Vascular, Inc. |
Nitric Oxide Releasing Polymer Composition
|
US20090232863A1
(en)
*
|
2008-03-17 |
2009-09-17 |
Medtronic Vascular, Inc. |
Biodegradable Carbon Diazeniumdiolate Based Nitric Oxide Donating Polymers
|
US20090240323A1
(en)
*
|
2008-03-20 |
2009-09-24 |
Medtronic Vascular, Inc. |
Controlled Degradation of Magnesium Stents
|
US8685995B2
(en)
|
2008-03-21 |
2014-04-01 |
The University Of Chicago |
Treatment with opioid antagonists and mTOR inhibitors
|
US20090253733A1
(en)
*
|
2008-04-02 |
2009-10-08 |
Biointeractions, Ltd. |
Rapamycin carbonate esters
|
NZ588671A
(en)
|
2008-04-11 |
2012-11-30 |
Emergent Product Dev Seattle |
Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
|
US20110098241A1
(en)
*
|
2008-04-14 |
2011-04-28 |
Poniard Pharmaceuticals, Inc. |
Rapamycin analogs as anti-cancer agents
|
US9789233B2
(en)
|
2008-04-17 |
2017-10-17 |
Micell Technologies, Inc. |
Stents having bioabsorbable layers
|
US20090269480A1
(en)
*
|
2008-04-24 |
2009-10-29 |
Medtronic Vascular, Inc. |
Supercritical Fluid Loading of Porous Medical Devices With Bioactive Agents
|
US20090297576A1
(en)
*
|
2008-06-02 |
2009-12-03 |
Medtronic Vascular, Inc. |
Local Delivery of PAR-1 Antagonists to Treat Vascular Complications
|
US20090299464A1
(en)
*
|
2008-06-02 |
2009-12-03 |
Medtronic Vascular, Inc. |
Reducing Bioabsorbtion Time of Polymer Coated Implantable Medical Devices Using Polymer Blends
|
EP2915532B1
(fr)
|
2008-06-17 |
2016-10-19 |
Wyeth LLC |
Combinaisons antinéoplasiques contenant du HKI-272 et de la vinorelbine
|
US20110152380A1
(en)
|
2008-06-20 |
2011-06-23 |
Kovarik John M |
Paediatric Compositions For Treating Multiple Sclerosis
|
WO2011009096A1
(fr)
|
2009-07-16 |
2011-01-20 |
Micell Technologies, Inc. |
Dispositif médical distributeur de médicament
|
CA2946195A1
(fr)
|
2008-07-17 |
2010-01-21 |
Micell Technologies, Inc. |
Dispositif medical d'administration de medicament
|
CN101676291B
(zh)
*
|
2008-09-18 |
2012-05-09 |
上海海和药物研究开发有限公司 |
一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途
|
EP2352459A4
(fr)
*
|
2008-10-03 |
2013-09-25 |
Elixir Medical Corp |
Composés lactones macrocycliques et leurs méthodes d'utilisation
|
US20100092534A1
(en)
*
|
2008-10-10 |
2010-04-15 |
Medtronic Vascular, Inc. |
Combination Local Delivery Using a Stent
|
US20100092535A1
(en)
*
|
2008-10-10 |
2010-04-15 |
Medtronic Vascular, Inc. |
Nanoporous Drug Delivery System
|
CN102292078A
(zh)
|
2008-11-11 |
2011-12-21 |
得克萨斯大学体系董事会 |
哺乳动物雷帕霉素靶蛋白的抑制
|
US20100131051A1
(en)
*
|
2008-11-24 |
2010-05-27 |
Medtronic Vascular, Inc. |
Systems and Methods for Treatment of Aneurysms Using Zinc Chelator(s)
|
US20100131001A1
(en)
*
|
2008-11-24 |
2010-05-27 |
Medtronic Vascular, Inc. |
Targeted Drug Delivery for Aneurysm Treatment
|
US20100152832A1
(en)
*
|
2008-12-12 |
2010-06-17 |
Medtronic Vascular, Inc. |
Apparatus and Methods for Treatment of Aneurysms With Fibrin Derived Peptide B-Beta
|
KR20110112352A
(ko)
|
2008-12-18 |
2011-10-12 |
노파르티스 아게 |
1-(4-{l-[(e)-4-시클로헥실-3-트리플루오로메틸-벤질옥시이미노]-에틸}-2-에틸-벤질)-아제티딘-3-카르복실산의 신규한 다형체 형태
|
BRPI0922466A2
(pt)
|
2008-12-18 |
2018-10-23 |
Novartis Ag |
sais
|
KR20170062554A
(ko)
|
2008-12-18 |
2017-06-07 |
노파르티스 아게 |
1-[4-[1-(4-시클로헥실-3-트리플루오로메틸-벤질옥시이미노)-에틸]-2-에틸-벤질]-아제티딘-3-카르복실산의 헤미푸마레이트 염
|
US8158187B2
(en)
*
|
2008-12-19 |
2012-04-17 |
Medtronic Vascular, Inc. |
Dry diazeniumdiolation methods for producing nitric oxide releasing medical devices
|
US20100198338A1
(en)
*
|
2009-01-30 |
2010-08-05 |
Medtronic Vascular, Inc., A Delaware Corporation |
Hydrogen Sulfide Donating Polymers
|
EP2393827B1
(fr)
|
2009-02-05 |
2015-10-07 |
Tokai Pharmaceuticals, Inc. |
Nouveaux promédicaments à base d'inhibiteurs cyp17 stéroïdiens/anti-androgènes
|
US20100227799A1
(en)
*
|
2009-03-09 |
2010-09-09 |
Medtronic Vascular, Inc. |
Simultaneous photodynamic therapy and photo induced polymerization
|
CA2757276C
(fr)
|
2009-04-01 |
2017-06-06 |
Micell Technologies, Inc. |
Endoprotheses enduites
|
US8236341B2
(en)
*
|
2009-04-02 |
2012-08-07 |
Medtronic Vascular, Inc. |
Poly(tetrafluoroethylene) polymer with nitric oxide donating surface
|
US20100256728A1
(en)
*
|
2009-04-07 |
2010-10-07 |
Medtronic Vascular, Inc. |
Semi-Permiable Biodegradable Stent Graft and Uses Thereof
|
US8709465B2
(en)
*
|
2009-04-13 |
2014-04-29 |
Medtronic Vascular, Inc. |
Diazeniumdiolated phosphorylcholine polymers for nitric oxide release
|
CN102481361B
(zh)
|
2009-04-16 |
2014-10-22 |
默沙东公司 |
用于治疗癌症的组合物和方法
|
WO2010132233A1
(fr)
|
2009-05-13 |
2010-11-18 |
The Trustees Of The University Of Pennsylvania |
Thérapie antinéoplasique combinée
|
JP2013501057A
(ja)
|
2009-08-03 |
2013-01-10 |
ユニバーシティー・オブ・マイアミ |
制御性t細胞のinvivoにおける増殖
|
US8754207B2
(en)
|
2009-09-25 |
2014-06-17 |
Cadila Healthcare Limited |
Process for the preparation of rapamycin derivatives
|
AU2010310786B2
(en)
|
2009-10-23 |
2014-03-27 |
Eli Lilly And Company |
AKT inhibitors
|
WO2011053938A1
(fr)
|
2009-10-30 |
2011-05-05 |
Ariad Pharmaceuticals, Inc. |
Procédés et compositions pour le traitement du cancer
|
US9283211B1
(en)
|
2009-11-11 |
2016-03-15 |
Rapamycin Holdings, Llc |
Oral rapamycin preparation and use for stomatitis
|
WO2015161139A1
(fr)
|
2014-04-16 |
2015-10-22 |
Rapamycin Holdings, Llc |
Préparation orale de rapamycine et utilisation pour une stomatite
|
EP2513225A4
(fr)
|
2009-12-18 |
2015-08-12 |
Interface Biologics Inc |
Administration locale de médicaments à partir de revêtements auto-assemblés
|
US8182830B2
(en)
*
|
2010-01-05 |
2012-05-22 |
Medtronic Vascular, Inc. |
Hydrogen sulfide generating polymers
|
EP2528906A2
(fr)
*
|
2010-01-28 |
2012-12-05 |
Fresenius Kabi Oncology Ltd |
Procédé de préparation de temsirolimus et de ses intermédiaires
|
WO2011097103A1
(fr)
|
2010-02-02 |
2011-08-11 |
Micell Technologies, Inc. |
Endoprothèse et système de pose d'endoprothèse avec une capacité améliorée de pose
|
US20130195919A1
(en)
|
2010-03-05 |
2013-08-01 |
President And Fellows Of Harvard College |
Induced dendritic cell compositions and uses thereof
|
WO2011133655A1
(fr)
|
2010-04-22 |
2011-10-27 |
Micell Technologies, Inc. |
Endoprothèses et autres dispositifs ayant un revêtement de matrice extracellulaire
|
EP2563391B1
(fr)
|
2010-04-27 |
2020-08-26 |
Roche Glycart AG |
Polythérapie d'un anticorps CD20 afucosylaté avec un inhibiteur mTOR
|
WO2011151704A2
(fr)
|
2010-06-02 |
2011-12-08 |
Fresenius Kabi Oncology Ltd. |
Compositions pharmaceutiques stables d'esters de rapamycine
|
US20130172853A1
(en)
|
2010-07-16 |
2013-07-04 |
Micell Technologies, Inc. |
Drug delivery medical device
|
US9321782B2
(en)
|
2010-08-04 |
2016-04-26 |
Meril Life Sciences Pvt. Ltd. |
Process for preparation of novel 42-O-(heteroalkoxyalkyl) rapamicin compounds with anti-proliferative properties
|
EP2608669B1
(fr)
|
2010-08-23 |
2016-06-22 |
Merck Sharp & Dohme Corp. |
Nouveaux dérivés de pyrazolo[1,5-a]pyrimidine utilisés comme inhibiteurs de mtor
|
JP2014503500A
(ja)
|
2010-11-18 |
2014-02-13 |
シンタ ファーマスーティカルズ コーポレーション |
低酸素状態に基づく酸素感受性薬剤による治療に適した被験体の事前選択
|
US20120128665A1
(en)
|
2010-11-18 |
2012-05-24 |
Synta Pharmaceuticals Corp. |
Preselection of subjects for therapeutic treatment based on hypoxic status
|
ES2423798T3
(es)
|
2010-11-19 |
2013-09-24 |
Universitätsklinikum Freiburg |
Hidrogeles de PEG disolubles sensibles a estímulos biofuncionalizados
|
CN102020662B
(zh)
*
|
2011-01-07 |
2013-02-13 |
天津市炜杰科技有限公司 |
一种驮瑞塞尔制备方法
|
KR102024948B1
(ko)
|
2011-02-18 |
2019-11-04 |
노파르티스 파르마 아게 |
mTOR/JAK 저해제 병용 요법
|
CA2828829A1
(fr)
*
|
2011-04-01 |
2012-10-04 |
Sandoz Ag |
Acylation regioselective de la rapamycine au niveau de la position c-42
|
US20140045847A1
(en)
|
2011-04-21 |
2014-02-13 |
Piramal Enterprises Limited |
Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
|
WO2012149014A1
(fr)
|
2011-04-25 |
2012-11-01 |
OSI Pharmaceuticals, LLC |
Utilisation de signatures de gènes de tem dans la découverte de médicaments contre le cancer, diagnostics et traitement du cancer
|
CA2838387A1
(fr)
|
2011-06-06 |
2012-12-13 |
Chevron Phillips Chemical Company Lp |
Utilisation de composes metallocenes pour le traitement du cancer
|
EP2532740A1
(fr)
|
2011-06-11 |
2012-12-12 |
Michael Schmück |
Préparations de lymphocytes T à mémoire centrale CD4+ et CD8+ spécifiques aux antigènes pour thérapie de lymphocyte T adoptif
|
WO2013012689A1
(fr)
|
2011-07-15 |
2013-01-24 |
Micell Technologies, Inc. |
Dispositif médical d'administration de médicament
|
WO2013013708A1
(fr)
|
2011-07-26 |
2013-01-31 |
Fundació Institut D'investigació Biomèdica De Bellvitge |
Traitement du rejet aigu dans une transplantation rénale
|
US10188772B2
(en)
|
2011-10-18 |
2019-01-29 |
Micell Technologies, Inc. |
Drug delivery medical device
|
CN102424829B
(zh)
*
|
2011-10-26 |
2013-10-16 |
苏州汉酶生物技术有限公司 |
一种酶催化合成坦西莫司的方法
|
US9642918B2
(en)
|
2011-12-16 |
2017-05-09 |
Pfizer Inc. |
Combination of inotuzumab ozogamicin and torisel for the treatment of cancer
|
GB201122305D0
(en)
|
2011-12-23 |
2012-02-01 |
Biotica Tech Ltd |
Novel compound
|
US10080805B2
(en)
|
2012-02-24 |
2018-09-25 |
Purdue Research Foundation |
Cholecystokinin B receptor targeting for imaging and therapy
|
US20140080175A1
(en)
|
2012-03-29 |
2014-03-20 |
Endocyte, Inc. |
Processes for preparing tubulysin derivatives and conjugates thereof
|
CN102796115B
(zh)
*
|
2012-05-25 |
2015-07-15 |
上海现代制药股份有限公司 |
一种坦西莫司的制备方法
|
CN103705925B
(zh)
|
2012-09-29 |
2018-03-30 |
段磊 |
抑制PI3K/AKT/mTOR信号通路的药物组合
|
US9750728B2
(en)
|
2012-09-29 |
2017-09-05 |
Targeted Therapeutics, Llc |
Method and pharmaceutical composition for inhibiting PI3K/AKT/mTOR signaling pathway
|
WO2014059295A1
(fr)
|
2012-10-12 |
2014-04-17 |
The Board Of Regents Of The University Of Texas System |
Utilisation d'inhibiteurs mtor pour traiter le déficit cognitif vasculaire
|
AU2013331440A1
(en)
|
2012-10-16 |
2015-04-30 |
Endocyte, Inc. |
Drug delivery conjugates containing unnatural amino acids and methods for using
|
EP2914260A1
(fr)
|
2012-10-31 |
2015-09-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Procédés pour prévenir le syndrome des antiphospholipides (sapl)
|
WO2014110258A1
(fr)
|
2013-01-09 |
2014-07-17 |
Podack Eckhard R |
Compositions et procédés pour la régulation de lymphocytes t régulateurs à l'aide d'une protéine d'une fusion tl1a-ig
|
JP6450690B2
(ja)
|
2013-02-15 |
2019-01-09 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
キメラ抗原受容体及びその使用方法
|
JP6330024B2
(ja)
|
2013-03-12 |
2018-05-23 |
マイセル・テクノロジーズ,インコーポレイテッド |
生体吸収性バイオメディカルインプラント
|
WO2014160328A1
(fr)
|
2013-03-13 |
2014-10-02 |
The Board Of Regents Of The University Of Texas System |
Inhibiteurs de mtor pour la prévention de la croissance de polypes intestinaux
|
KR20150127720A
(ko)
|
2013-03-14 |
2015-11-17 |
유니버시티 오브 매릴랜드, 발티모어 |
안드로겐 수용체 하향 조절제 및 그의 용도
|
WO2014182635A1
(fr)
|
2013-05-08 |
2014-11-13 |
Baldwin Megan E |
Marqueurs biologiques de la dégénérescence maculaire liée à l'âge (dmla)
|
US10272606B2
(en)
|
2013-05-15 |
2019-04-30 |
Micell Technologies, Inc. |
Bioabsorbable biomedical implants
|
CN103421023B
(zh)
*
|
2013-07-30 |
2015-09-23 |
福建省微生物研究所 |
一种替西罗莫司的合成工艺
|
BR112016002970A2
(pt)
|
2013-08-12 |
2017-09-12 |
Tokai Pharmaceuticals Inc |
biomarcadores para o tratamento de distúrbios neoplásicos que usa terapias direcionadas ao androgênio
|
EP3068435A1
(fr)
|
2013-11-13 |
2016-09-21 |
Novartis AG |
Inhibiteurs de mtor ameliorant la reponse immunitaire
|
EP2878312A1
(fr)
|
2013-12-02 |
2015-06-03 |
Albert-Ludwigs-Universität Freiburg |
Nanosupports de PEGylation réversible
|
RU2714902C2
(ru)
|
2013-12-19 |
2020-02-20 |
Новартис Аг |
Химерные рецепторы антигена против мезотелина человека и их применение
|
JP6793902B2
(ja)
|
2013-12-20 |
2020-12-02 |
ノバルティス アーゲー |
調節可能キメラ抗原受容体
|
US9700544B2
(en)
|
2013-12-31 |
2017-07-11 |
Neal K Vail |
Oral rapamycin nanoparticle preparations
|
CA3206208A1
(fr)
|
2013-12-31 |
2015-07-09 |
Rapamycin Holdings, Llc |
Preparations orales de nanoparticules de rapamycine, et utilisation
|
EP3094314B1
(fr)
|
2014-01-16 |
2021-06-23 |
MUSC Foundation For Research Development |
Nanosupports ciblés pour l'administration d'agents immunosuppresseurs
|
WO2015142661A1
(fr)
|
2014-03-15 |
2015-09-24 |
Novartis Ag |
Récepteur d'antigène chimèrique régulable
|
EP3593812A3
(fr)
|
2014-03-15 |
2020-05-27 |
Novartis AG |
Traitement du cancer à l'aide d'un récepteur d'antigène chimérique
|
CA2943609A1
(fr)
|
2014-03-27 |
2015-10-01 |
The Brigham And Women's Hospital, Inc. |
Conjugues de medicaments actives metaboliquement pour vaincre la resistance dans une therapie du cancer
|
KR20240042250A
(ko)
|
2014-04-07 |
2024-04-01 |
노파르티스 아게 |
항-cd19 키메라 항원 수용체를 사용한 암의 치료
|
CA2950589A1
(fr)
|
2014-06-02 |
2015-12-10 |
Children's Medical Center Corporation |
Procedes et compositions pour une immunomodulation
|
JP2017528433A
(ja)
|
2014-07-21 |
2017-09-28 |
ノバルティス アーゲー |
低い免疫増強用量のmTOR阻害剤とCARの組み合わせ
|
CN107109419B
(zh)
|
2014-07-21 |
2020-12-22 |
诺华股份有限公司 |
使用cd33嵌合抗原受体治疗癌症
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
CN104086564B
(zh)
*
|
2014-07-30 |
2019-02-05 |
江苏奥赛康药业股份有限公司 |
一种高纯度坦罗莫司的制备方法
|
US20170209492A1
(en)
|
2014-07-31 |
2017-07-27 |
Novartis Ag |
Subset-optimized chimeric antigen receptor-containing t-cells
|
WO2016025880A1
(fr)
|
2014-08-14 |
2016-02-18 |
Novartis Ag |
Traitement du cancer à l'aide du récepteur d'antigène chimérique gfr alpha-4
|
SG11201700770PA
(en)
|
2014-08-19 |
2017-03-30 |
Novartis Ag |
Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
|
EP3193902A4
(fr)
|
2014-09-11 |
2018-03-28 |
The Regents of The University of California |
Inhibiteurs de mtorc1
|
US10577417B2
(en)
|
2014-09-17 |
2020-03-03 |
Novartis Ag |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
EP2997977A1
(fr)
|
2014-09-19 |
2016-03-23 |
Fundación de la Comunidad Valenciana Centro de Investigación Principe Felipe |
Inhibiteurs de MTOR spécifiques dans le traitement d'une adrénoleucodystrophie à liaison X
|
JP6815992B2
(ja)
|
2014-10-08 |
2021-01-20 |
ノバルティス アーゲー |
キメラ抗原受容体療法に対する治療応答性を予測するバイオマーカーおよびその使用
|
US20190054117A1
(en)
|
2014-12-19 |
2019-02-21 |
Novartis Ag |
Dimerization switches and uses thereof
|
US10377818B2
(en)
|
2015-01-30 |
2019-08-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Method of treating glioma
|
EP3280795B1
(fr)
|
2015-04-07 |
2021-03-24 |
Novartis AG |
Combinaison de traitement à l'aide du récepteur antigénique chimérique et de derivés de l'amino pyrimidine
|
US11896614B2
(en)
|
2015-04-17 |
2024-02-13 |
Novartis Ag |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
EP3286211A1
(fr)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Traitement du cancer à l'aide de protéine récepteur antigénique chimérique et un inhibiteur de protéine kinase
|
AU2016263176A1
(en)
|
2015-05-20 |
2017-12-07 |
Novartis Ag |
Pharmaceutical combination of everolimus with dactolisib
|
US10392607B2
(en)
|
2015-06-03 |
2019-08-27 |
The Regents Of The University Of California |
Cas9 variants and methods of use thereof
|
WO2017029391A1
(fr)
|
2015-08-20 |
2017-02-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Nouvelle méthode de traitement du cancer
|
AU2016352806A1
(en)
|
2015-11-11 |
2018-05-10 |
Novartis Ag |
Uses of myostatin antagonists, combinations containing them and uses thereof
|
US10765665B2
(en)
|
2015-11-24 |
2020-09-08 |
Melin Jeffrey |
Composition comprising combination of rapamycin and an activator of AMP kinase and use thereof for treating diseases
|
WO2020047527A2
(fr)
|
2018-09-02 |
2020-03-05 |
F1 Bioventures, Llc |
Procédés et compositions pour modifier génétiquement des lymphocytes dans le sang ou dans des pbmc enrichies
|
CA3031542A1
(fr)
|
2016-07-20 |
2018-01-25 |
University Of Utah Research Foundation |
Lymphocytes car-t cd229 et leurs procedes d'utilisation
|
CN109996549A
(zh)
|
2016-09-22 |
2019-07-09 |
墨卡托医疗系统公司 |
使用坦罗莫司治疗再狭窄
|
CN117866991A
(zh)
|
2016-10-07 |
2024-04-12 |
诺华股份有限公司 |
用于治疗癌症的嵌合抗原受体
|
WO2018096402A1
(fr)
|
2016-11-23 |
2018-05-31 |
Novartis Ag |
Méthodes d'amélioration de la réponse immunitaire à l'évérolimus, au dactolisib ou aux deux
|
JP2020507632A
(ja)
|
2017-02-10 |
2020-03-12 |
マウント タム セラピューティクス, インコーポレイテッドMount Tam Therapeutics, Inc. |
ラパマイシン類似体
|
CA3054064A1
(fr)
|
2017-03-03 |
2018-09-07 |
F1 Oncology, Inc. |
Procedes et compositions pour la transduction et l'expansion de lymphocytes et la regulation de l'activite de ces derniers
|
EP3615055A1
(fr)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Cellules exprimant un récepteur antigénique chimérique ciblant le bcma, et polythérapie comprenant un inhibiteur de gamma sécrétase
|
ES2871499T3
(es)
|
2017-05-15 |
2021-10-29 |
Bard Inc C R |
Dispositivo médico con recubrimiento de elución de fármaco y capa intermedia
|
CN108948045A
(zh)
*
|
2017-05-20 |
2018-12-07 |
鲁南制药集团股份有限公司 |
一种替西罗莫司的制备方法
|
KR20200008166A
(ko)
|
2017-05-26 |
2020-01-23 |
머케이터 메드시스템즈, 인크. |
재협착의 치료를 위한 조합 요법
|
EP3644997A1
(fr)
|
2017-06-26 |
2020-05-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Méthodes et compositions pharmaceutiques de traitement du syndrome d'olmsted
|
WO2019012024A1
(fr)
|
2017-07-13 |
2019-01-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Procédés pour augmenter l'expansion et la capacité immunosuppressive d'une population de tregs cd8+cd45rcbas/-
|
AR112834A1
(es)
|
2017-09-26 |
2019-12-18 |
Novartis Ag |
Derivados de rapamicina
|
WO2019157516A1
(fr)
|
2018-02-12 |
2019-08-15 |
resTORbio, Inc. |
Polythérapies
|
CN110382019B
(zh)
|
2018-03-14 |
2020-08-25 |
墨卡托医疗系统公司 |
用于局部药物递送的医疗器械和医疗方法
|
US20210047405A1
(en)
|
2018-04-27 |
2021-02-18 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
WO2019213282A1
(fr)
|
2018-05-01 |
2019-11-07 |
Novartis Ag |
Biomarqueurs pour évaluer des cellules car-t pour prédire un résultat clinique
|
CN112368289B
(zh)
|
2018-05-01 |
2024-02-20 |
锐新医药公司 |
作为mtor抑制剂的c26-连接的雷帕霉素类似物
|
CR20200578A
(es)
|
2018-05-01 |
2021-02-22 |
Revolution Medicines Inc |
Análogos de rapamicina a c40, c28 y c32 como inhibidores de mtor
|
WO2019222843A1
(fr)
|
2018-05-22 |
2019-11-28 |
Interface Biologics, Inc. |
Compositions et procédés d'administration de médicaments à une paroi de vaisseau
|
JP2022510573A
(ja)
|
2018-07-23 |
2022-01-27 |
エンクリアー セラピーズ, インク. |
神経障害の治療方法
|
EP3826650A4
(fr)
|
2018-07-23 |
2022-07-27 |
Enclear Therapies, Inc. |
Méthodes de traitement de troubles neurologiques
|
US20220047567A1
(en)
|
2018-09-10 |
2022-02-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of neurofibromatosis
|
EP3632460A1
(fr)
|
2018-10-05 |
2020-04-08 |
St. Anna Kinderkrebsforschung |
Groupe de récepteurs d'antigènes chimériques (cars)
|
CN113164576A
(zh)
|
2018-10-05 |
2021-07-23 |
圣安娜儿童癌症研究中心 |
嵌合抗原受体(car)组
|
EP3632461A1
(fr)
|
2018-10-05 |
2020-04-08 |
St. Anna Kinderkrebsforschung |
Groupe de récepteurs d'antigène chimérique (cars)
|
KR20210072797A
(ko)
|
2018-10-05 |
2021-06-17 |
세인트 안나 킨더크렙스포르슝 |
키메라 항원 수용체(car) 그룹
|
EP3880266A1
(fr)
|
2018-11-14 |
2021-09-22 |
Lutonix, Inc. |
Dispositif médical avec revêtement à élution de médicament sur un dispositif à surface modifiée
|
US20220040324A1
(en)
|
2018-12-21 |
2022-02-10 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate and kinase inhibitor
|
WO2020209828A1
(fr)
|
2019-04-08 |
2020-10-15 |
Bard Peripheral Vascular, Inc. |
Dispositif médical portant un revêtement d'élution de médicament sur une surface modifiée de dispositif
|
AU2020271894A1
(en)
|
2019-04-11 |
2021-12-02 |
Enclear Therapies, Inc. |
Methods of amelioration of cerebrospinal fluid and devices and systems therefor
|
CN113372359A
(zh)
*
|
2020-03-10 |
2021-09-10 |
鲁南制药集团股份有限公司 |
一种坦西莫司的制备方法
|
WO2022098642A1
(fr)
|
2020-11-03 |
2022-05-12 |
Rdiscovery, LLC |
Thérapies pour le traitement du cancer et de maladies associées à une déficience en phagocytose
|
CA3223081A1
(fr)
|
2021-07-15 |
2023-01-19 |
Samir Mitragotri |
Compositions et methodes associees a des cellules comprenant des particules adherees
|
WO2024008799A1
(fr)
|
2022-07-06 |
2024-01-11 |
Institut National de la Santé et de la Recherche Médicale |
Méthodes de traitement de la glomérulonéphrite proliférative
|
WO2024028433A1
(fr)
|
2022-08-04 |
2024-02-08 |
Institut National de la Santé et de la Recherche Médicale |
Procédés de traitement de troubles lymphoprolifératifs
|
WO2024100236A1
(fr)
|
2022-11-11 |
2024-05-16 |
Astrazeneca Ab |
Polythérapies pour le traitement du cancer
|